Brendan Curley DO, MPH
@drcurley.bsky.social
Medical Oncologist/Hematologist
Opinions = my own
PGY-19 #medtwitter #medsky
Drink the wine, burn the candles, take the trip.
Opinions = my own
PGY-19 #medtwitter #medsky
Drink the wine, burn the candles, take the trip.
Tylenol does not cause autism. Full stop.
Acetaminophen/Tylenol use during pregnancy was not associated with children’s risk of autism, ADHD, or intellectual disability in sibling control analysis. This suggests associations observed in other, less rigorous analyses may have been attributable to familial confounding (aka erroneous finding):
Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability
This nationwide cohort study with sibling control analysis examines the association of acetaminophen use during pregnancy with children’s risk of autism, ADHD, and intellectual disability.
jamanetwork.com
September 6, 2025 at 12:41 AM
Tylenol does not cause autism. Full stop.
Reposted by Brendan Curley DO, MPH
FDA has granted accelerated approval to datopotamab deruxtecan (Dato‑DXd) for EGFR‑mutated NSCLC, marking a promising new option in lung cancer care. Kudos to Dr.
@sands_jacob
and team on this milestone. ascopost.com/news/june-20... #LungCancer #OncologyNews
@sands_jacob
and team on this milestone. ascopost.com/news/june-20... #LungCancer #OncologyNews
June 24, 2025 at 3:15 PM
FDA has granted accelerated approval to datopotamab deruxtecan (Dato‑DXd) for EGFR‑mutated NSCLC, marking a promising new option in lung cancer care. Kudos to Dr.
@sands_jacob
and team on this milestone. ascopost.com/news/june-20... #LungCancer #OncologyNews
@sands_jacob
and team on this milestone. ascopost.com/news/june-20... #LungCancer #OncologyNews
Reposted by Brendan Curley DO, MPH
Presented at #ASCO25:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
nej.md
May 30, 2025 at 9:05 AM
Presented at #ASCO25:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results: